GI Biome plans begin administering the first patient in a phase 1 clinical trial of a microbiome-based colorectal cancer treatment candidate in April.

GI Biome held an investment briefing session at the GI Biome headquarters on the 27th and disclosed the development status of ‘GB-104 (development name GB-X01)', a microbiome-based colorectal cancer drug candidate. Yuhan Corporation, Maeil Dairies (Maeil Holdings), Cloud IB, Shinhan Venture Investment, Samsung Securities, and Cheil Industries attended the briefing session on this day.

Read more: https://www.docdocdoc.co.kr/news/articleView.html?idxno=3003108